Random Clinical Trials Are Not The Only Answer To Identifying Effective Therapies


Medicine in the United States is, in part, safeguarded by theFood and Drug Administration (FDA). The FDA serves admirably as a protection against charlatans and ineffective treatments through the use of clinical trials that filter out dangerous drugs and identify safe, effective therapies.

The FDA’s work has a direct impact on health insurance coverages, including Medicare. The efficacy of its screening procedures are of intense importance. These procedures largely rest on double-blind, random clinical trials (RCT) that can yield statistically powerful evidence about the efficacy and safety of a drug.

In a forthcoming post I hope to discuss recent work with colleagues that starts to examine where random clinical trials fail, and what to do when that happens. This is a subject I touched on in my last post, “Should The FDA Rethink How It Runs Clinical Trials?”. Read more